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Hypoxia Inducible Factor (HIF) is a 
heterodimeric transcription factor that 
activates the cellular response to hypoxia. 
The HIF1α subunit is constantly synthesized 
and degraded under normoxia, but 
degradation is rapidly inhibited when oxygen 
levels drop. Oxygen-dependent 
hydroxylation by Prolyl-4-hydroxylases 
(PHD) mediates HIF1α proteasome 
degradation. Brain ischemia limits the 
availability not only of oxygen but also of 
glucose. We hypothesised that the 
concurrent absence of glucose and oxygen 
could have a modulating effect on HIF. We 
studied HIF1α in differentiated 
neuroblastoma cells subjected to ischemia 
and assessed the separate involvement of 
oxygen and glucose in HIF1α regulation. We 
report higher transcriptional activity and 
HIF1α expression under oxygen deprivation 
in the presence of glucose (OD), than in its 
absence (oxygen and glucose deprivation, 
OGD). Unexpectedly, HIF1α was not 
degraded at reoxygenation after an episode 
of OGD. This was not due to impairment of 
proteasome function, but was associated with 
lower HIF1α hydroxylation. Krebs cycle 
metabolites fumarate and succinate are 
known inhibitors of PHD, while α-
ketoglutarate is a co-substrate of the 
reaction. Lack of HIF1α degradation in the 
presence of oxygen was accompanied by a 
very low α-ketoglutarate/fumarate ratio. 
Furthermore, treatment with a fumarate 
analogue prevented HIF1α degradation 
under normoxia. In all, our data suggest that 
postischemic metabolic alterations in Krebs 
cycle metabolites impair HIF1α degradation 
in the presence of oxygen by decreasing the 
hydroxylation status of HIF1α. Besides the 
well-known effect of oxygen promoting 
HIF1α degradation, our results highlight the 
involvement of metabolic pathways in HIF1α 
regulation.  
The hypoxia-inducible transcription 
factor (HIF) is expressed at very low levels in 
cells under normal oxygen tension, but is 
rapidly induced upon exposure to hypoxia (1), 
triggering the activation of a genetic 
programme that enables the metabolic 
adaptation of cells (2). HIF is a heterodimeric 
factor composed of a hypoxia-regulated α 
subunit (HIF1α or HIF2α) and constitutively 
expressed HIF1β (also known as aryl 
hydrocarbon receptor nuclear translocator, 
ARNT) (2). Although the α subunit is 
constantly transcribed and translated, it is also 
degraded in an oxygen-dependent mechanism. 
It is only with dwindling oxygen levels that 
HIF1α or HF2α expression is readily detected 
(3). In the presence of oxygen, HIF prolyl-
hydroxylases (PHD) hydroxylate two proline 
residues (positions 402 and 564 in human 
HIF1α), in a reaction that requires molecular 
oxygen and α-ketoglutarate as co-substrates (4). 
These hydroxyproline residues are recognised 
by the Von Hippel-Lindau tumor suppressor 
protein (pVHL), one of the components of a E3 
ubiquitin-ligase complex that also contains 
elongins B and C, cullin2 and Rbx, which 
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conjugates ubiquitin to HIFα (4;5). This results 
in the oxygen-dependent targeting of HIFα to 
the proteasome. Decreased oxygen 
concentration results in impaired prolyl-
hydroxylation, reduced targeting of HIFα to the 
proteasome and the accumulation of HIF in the 
nucleus, where it activates a plethora of genes 
devoted to improving the delivery of oxygen 
and enhancing the production of ATP by 
glycolysis, among other actions (6).  
HIF1 is a key component of the cellular 
response to brain ischemia (7) and may play 
role on survival. Thus, permanent MCA1 
occlusion in rats induces a temporal and spatial 
co-induction of the mRNA of HIF1α and those 
of target genes, such as glucose transporter 1 
(GLUT1) and glycolytic enzymes (8) in the 
penumbral area. This is further supported by the 
increased damage in a model of transient MCA 
occlusion in mice with neuron-specific 
inactivation of HIF1α (9). In contrast, a 
truncated form of HIF1α with dominant-
negative effects reduced delayed cell death in 
cultured neurons subjected to OGD (10), 
through effects on p53 expression (11;12), and 
HIF1α-deficient mice were protected against 
ischemic brain damage (13). However, 
expression of the majority of hypoxia-
dependent genes was unaffected in these mice 
whereas apoptotic genes were specifically 
down-regulated, suggesting a predominant pro-
apoptotic role of HIF1α.  
Much of the knowledge on the 
mechanisms that regulate the expression of HIF 
owing to changing oxygen levels has been 
obtained from cultured cell models where the 
availability of glucose was not restricted, and 
less attention has been comparatively paid to 
the fact that under ischemia, a shortage of 
oxygen coincides with a limiting availability of 
glucose, particularly in cells with low glycogen 
storage such as neural cells. We hypothesised 
that the concurrent absence of glucose and 
oxygen could have a modulating effect on the 
expression of HIF.  
 
 Experimental Procedures 
 
Materials- Dimethyloxallyl Glycine (DMOG) 
was purchased from Cayman Chemical. All-
trans retinoic acid (RA) and MG132 were from 
Calbiochem. Diethyl ether was purchased from 
Merck and Ethyl acetate was purchased from 
J.T. Baker.  All other chemicals were purchased 
from Sigma, whilst tissue culture reagents were 
ordered from Invitrogen.  
Cell Culture- The culture and RA-
induced differentiation of SH cells in our model 
has previously been described (14). The wild 
type renal cell carcinoma (RCC4) line and a 
derivative clone stably transfected with an 
expression vector for pVHL were obtained from 
the European Collection of Cell Cultures 
(ECACC/Sigma). These cells were grown in 
low-glucose (5.6 mM) DMEM supplemented 
with 10% fetal bovine serum, 100 U/mL 
penicillin, 100 μg/mL streptomycin, 1 mM 
sodium pyruvate, and 500 μg/mL G418. 
Anoxia plus reoxygenation 
experiments- SH cells seeded on 6 cm Petri 
dishes (14) were subjected to 15h anoxia either 
in glucose-containing or glucose-free medium 
as described (14). This was followed by 
reoxygenation where indicated, with no 
intervening change in the media that had been 
used during the incubation in anoxia. For the 
experiments performed with RCC4 cells, 105 
cells per 6 cm Petri dish were seeded three days 
before the experiment in 5 ml of the growth 
medium described above. Just before the 
experiment, cells were washed once in either 
growth medium with standard glucose 
concentration or growth medium prepared with 
glucose-free DMEM. This volume was 
aspirated and cells were added another three ml 
of either of the media and assigned to the 
glucose-containing or glucose-free groups. 
Anoxia and reoxygenation were carried out in 
the same way as for SH cells.  
Total cell extracts- At the end of the 
anoxia and reoxygenation experiments 
described above, total cell extracts were 
prepared for the analysis of protein expression 
by western blotting. The procedure was carried 
out while keeping the cells on ice at all times. 
Since cells that had been subjected to OGD 
conditions were loosely attached to the surface, 
these were scraped off the dish in a small 
volume of medium, briefly spun at 4ºC, the cell 
pellet was resuspended in one ml of cold 
phosphate-buffered saline (PBS), spun again, 
and finally resuspended in 1.5x Laemmli 
 3
sample buffer for SDS-PAGE (150mM 
Tris·HCl pH 6.8, 1.5% SDS, 15% glycerol, no 
bromphenol blue) to lyse the cells.  Cells that 
had been kept in control conditions or that had 
been subjected to anoxia in the presence of 
glucose were more firmly attached to the 
surface so cells were washed in PBS whilst still 
adhered to the Petri dish, and directly lysed 
with 200 μl of 1.5X Laemmli sample buffer. All 
lysates were briefly sonicated in order to reduce 
their viscosity, and incubated at 100ºC for 5’. 
Protein concentration was quantitated by using 
the BCA protein assay (Thermo Scientific).  
Western blotting- Twenty μg of protein 
from total cellular extracts was loaded on SDS-
PAGE gels.  Western blotting was carried out 
as previously described (14), except for the 
detection of the hydroxylated Pro564-HIF, where 
the membrane was blocked overnight at 4ºC in 
5% skimmed milk in T-TBS, then incubated 
with the primary antibody (1:1000) for 2.5h at 
RT in 1% skimmed milk in T-TBS. Detection 
of the signal in this case was carried out with 
the SuperSignal West Dura Extended Duration 
Substrate (Thermo Scientific) and a Versadoc 
imaging system (BioRad). Antibodies raised 
against the following proteins were used at the 
dilutions indicated: HIF1α (Novus Biologicals; 
NB100-449, 1:2000), HIF1β (Abcam; ab2771, 
1:1000), GLUT1 (Abcam, ab652, 1:1000), 
Hexokinase II (Santa Cruz Biotechnology; sc-
6521, 1:1000), α-actin (Assay 
Designs/Stressgene; CSA-400, 1: 5000), ATP 
synthase-β (BD Biosciences; #612518, 1:1000), 
hydroxy-Pro564-HIF (Cell Signalling; #3434, 
1:1000), PHD2 (Novus Biologicals; NB100-
138, 1:1000), β-tubulin (Sigma; T-4026, 
1:50000), GFP (Abcam, ab290, 1:5000).  
Quantification of VEGF by ELISA- 
Secreted VEGF was quantitated in the culture 
medium of SH cells after incubation under 
anoxic conditions. This was performed by using 
the Quantikine Human VEGF Immunoassay 
(R&D Systems), and according to the 
manufacturer’s instructions. Results were 
represented as fold activation over the control 
group.  
Quantification of HIF1α abundance- 
The Surveyor IC intracellular Human/Mouse 
total HIF1α immunoassay (R&D Systems)  was 
used to quantitate HIF1α expression, according 
to the manufacturer’s instructions. Extracts 
were prepared from RA-differentiated SH cells 
seeded at 3x105 cells per six cm Petri dish. A 
standard curve obtained with known amounts of 
HIF1α was run in parallel to the samples in 
every assay so that expression of HIF1α could 
be expressed as pg of HIF1α per μg of total 
cellular protein. Total cellular protein 
concentration in the lysates was quantitated 
with Bradford’s assay (Bio-Rad laboratories).  
HIF1 binding assays- Binding of HIF1 
in nuclear extracts to an oligonucleotide 
containing an HRE was analysed with the 
TransAM HIF-1 Transcription Factor Assay Kit 
(Active Motif). SH cells were treated as above. 
At the end of the experiment, cells were placed 
on ice and nuclear extracts were prepared 
according to the manufacturer’s instructions 
with minor modifications. Cells were harvested 
by scraping and washed once in cold PBS. The 
cell pellet was resuspended in 400 μl of a 
hypotonic solution (10mM HEPES, 10mM 
KCl, 0.1mM EDTA), kept on ice for 20 min, 
and Igepal CA-630 was then added to a 0.02% 
final concentration. The suspension was briefly 
mixed by inversion and immediately 
centrifuged at 11,000 g for 1 min at 4ºC. The 
nuclear pellet was resuspended in 50 μl of the 
lysis buffer provided in the kit (supplemented 
with DTT and protease inhibitors provided). 
Nuclei were incubated for 30 min on ice with 
occasional mixing by inversion, and centrifuged 
for 10 min at 14,000 g, 4ºC. The supernatant 
was saved as nuclear extract, and stored in 
aliquots at –80ºC until assayed. Protein content 
of the extracts was assayed with Bradford’s 
assay (Bio-Rad laboratories).  
Transcriptional reporter assays- 
Relative HIF transcriptional activity was 
analysed by performing transient transfections 
into SH cells with a plasmid that expressed 
firefly luciferase under the control of the basic 
c-fos promoter and a 29 bp enhancer from the 
pfkfb3 gene that contains two HRE, cloned 
upstream (15). Control vectors included a 
vector that did not contain an HRE but only the 
c-fos basal promoter, and another one 
containing a mutated HRE that does not bind 
HIF (15). pRL-CMV (Promega), a constitutive 
expression vector for Renilla reniformis 
luciferase  was used to normalise the  efficiency 
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of transfection. For transfection, cells were 
seeded on 24-well plates at a density of 40,000 
cells per well, and allowed to differentiate with 
RA for 3 days. On the fourth day, a total of one 
μg of DNA (900 ng of firefly luciferase reporter 
vector plus 100 ng of pRL-CMV) per well was 
transfected with Superfect reagent (Qiagen), 
according to the manufacturer’s instructions. 
The transfection mix was on the cells for three 
hours and at the end of the transfection, RA was 
added back to the medium to resume 
differentiation for the usual total of five days.  
Anoxia experiments were performed as 
described above and lysates were prepared and 
analysed by using the Dual-Glo kit (Promega), 
according to the manufacturer’s instructions. 
Stable transfection- Expression vectors 
for the fusion proteins Ub-G76V-EGFP 
(Addgene plasmid  11941) and Ub-M-EGFP 
(Addgene plasmid 11938) were obtained from 
N. Dantuma (16) through Addgene.  One 
million SH cells seeded on 10 cm Petri dishes 
were transfected as described in the preceding 
section with 10 μg of plasmid and selected with 
400 μg/mL G418 to generate clones with stable 
expression of either of the vectors.  
Metabolite Quantification- Analysis of 
α-ketoglutarate, succinate and fumarate was 
carried out by gas chromatography-mass 
spectrometry (GC-MS) detection of ketoacids 
with a method adapted from refs. (17;18). 
Experiments were performed on SH cells 
seeded at 3x106 in 10 cm Petri dishes, which 
had been differentiated with 10 μM RA as 
described (14). At the end of the incubations, 
cells were washed with PBS and the cell pellet 
was resuspended in 500 µl of milli-Q water and 
frozen at -20ºC until assayed (a separate 
fraction was set aside for protein 
quantification). For the preparation of extracts, 
the 500 µl samples were taken to a volume of 
two ml with water, and further added one mL of 
8M NaOH and one mL of 25 mg/mL 
hydroxylamine. The sample was then heated at 
60ºC for 30 min, and pH was adjusted by 
adding one mL of 6N HCl. Sequential 
extractions were carried out as described (18) 
with the exception that samples were extracted 
twice with two mL diethyl ether and twice with 
two mL ethylacetate. Six µL of 5 mM 
Undecanoic acid was added at the collection 
tube to serve as an internal standard of the 
procedure. Once completely evaporated with 
nitrogen gas, the final dry residue was 
resuspended in 75 μl of trimethylsilyl, 
incubated at 60ºC for 30 min to derivatize the 
keto-acids, and kept at -20ºC until injected. 
Two μL samples were injected into a 7890A-
5975C GC-MS (Agilent Technologies), with an 
HP-5MS 60x 0.25x 0.25 capillary column using 
a splitless method and pressure ramp, and 
results were analysed by using the ChemStation 
GC/MSD software. The ratio between the areas 
(area of the peak corresponding to each acid 
and the area of undecanoic acid) was 
normalised by the protein concentration of the 
sample (μg/μl).  
Statistical Analysis- Data analysis was 
performed with GraphPad Prism software 
(GraphPadSoftware), by either one-way 
ANOVA, followed by post-hoc analysis with 
Bonferroni Multiple Comparison test; Mann-
Whitney non-parametric test; or Krustall-Wallis 
test for non parametric data followed by a 
Dunn’s multiple comparison test, as indicated 
in the figure legends.  
 
RESULTS 
 
The availability of glucose during 
incubation of SH cells under anoxia affects the 
activation of HIF1α and its target genes. We 
examined the expression of HIF1α protein in 
total cellular extracts obtained from RA-
differentiated SH cells that were incubated for 
15h under anoxia in either the presence or the 
absence of glucose. HIF1α was not expressed 
under control conditions but was induced by 
anoxia (Figure 1A). The induction was more 
intense in OD conditions than in OGD (Figure 
1A). On the other hand, the expression of 
HIF1β showed no differences under any of the 
conditions assayed (Figure 1A). Densitometry 
of the western blots showed a 4.5-fold higher 
expression of HIF1α in the OD than in the OGD 
group (Figure 1B).   Since western blotting only 
offers semi-quantitative data, we quantitated 
HIF1α by ELISA. HIF1α increased from non-
detectable levels under control conditions to 
17.3±4.8 pg of HIF1α per µg of total cellular 
protein (Figure 1C) under OD. Cells under 
OGD displayed a much smaller increase 
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(0.5±0.1 pg of HIF1α per µg of total cellular 
protein, figure 1C).  FACS-analysis of cells 
incubated with pimonidazole during anoxia 
showed that oxygen availability was similarly 
reduced in the OD and OGD groups, showing 
that those differences in HIF1α expression were 
not caused by differences in the oxygen 
concentration available to the cells 
(Supplementary figure S1). Since the 
transcriptional effects of HIF1 are dependent on 
the α/β heterodimer binding to DNA (19), we 
analysed the binding of HIF1 from nuclear 
extracts to an oligonucleotide containing an 
HRE. Our data correlated with the abundance of 
HIF1α, with stronger binding to DNA in the 
presence than in the absence of glucose during 
anoxia (Figure 1D). The expression of HIF1α in 
the same nuclear extracts paralleled the binding 
results (data not shown), and was in the range 
of the data presented in figures 1A and 1B.  
Furthermore, HIF transcriptional activity 
behaved accordingly with the HIF1α expression 
data. Thus, in transient transfection experiments 
with a luciferase reporter vector under the 
control of the pfkfb3 HRE (wtHRE), the OD 
caused an approximately 74-fold increase in 
transcription (Figure 2A). In contrast, cells 
under OGD conditions only reached seven-fold 
activation in transcription (Figure 2A). The 
effects were specifically related to HIF activity 
since they were abolished when the HRE was 
mutated (mutHRE, Figure 2A). In keeping with 
this, we tested the expression of known 
endogenous HIF transcriptional targets (20). 
Firstly, we examined the secretion of VEGF 
into the culture media at the end of anoxia. OD 
brought about a 24-fold higher secretion of 
VEGF, and OGD just a 5-fold induction (Figure 
2B). Similarly to VEGF, GLUT1 and 
hexokinase 2 were induced after incubating SH 
cells under OD, but the absence of glucose in 
OGD dampened the increase in expression 
(Figure 2C). Our data support that differences 
in the expression levels of HIF1α achieved 
under OD or OGD correlate with HIF activity 
and the expression of HIF-target genes. 
HIF1α expressed under OGD 
conditions is not readily degraded after 
reoxygenation. Since the availability of glucose 
affected the abundance of HIF1α during anoxia, 
we explored whether any differences may 
persist after an additional incubation under 
normoxic conditions (reoxygenation).  Thus, we 
examined the expression of HIF1α protein at 
different times after reoxygenation. HIF1α was 
fully degraded one h after reoxygenation 
following OD (Figure 3A). Unexpectedly, the 
HIF1α expressed after OGD was not degraded 
and was still detectable at least six h after 
reoxygenation (Figure 3A). This effect was 
only observed after a long period of OGD 
(15h), since SH cells subjected to a six h OGD 
completely degraded HIF1α within 30 min of 
reoxygenation (Figure 3B). Furthermore, the 
persistence of HIF1α was strictly dependent on 
the induction of anoxia, since hypoxic 
conditions of 1.0% oxygen were not able to 
prevent HIF1α degradation after reoxygenation 
(Supplementary figure S2).  
The persistence of HIF1α after 
reoxygenation is not due to inhibition of 
proteasome activity. Since the ubiquitin-
proteasome pathway is HIF1α’s main and best 
characterised degradation system (21), we 
examined its functionality in our model to see if 
the stabilisation of HIF1α could result from 
inhibition of the proteasome activity. To this 
end, we generated SH clones with stable 
expression of a proteasome activity reporter 
consisting of a ubiquitin-EGFP fusion protein 
(UbG76V-EGFP SH) (16). The ubiquitin 
moiety in this reporter contains a gly to val 
substitution at position 76 that prevents 
cleavage by ubiquitin hydrolases, so it commits 
the fusion protein to constitutive proteasomal 
degradation. Consequently, no EGFP 
fluorescence was observed under control 
conditions (Figure 4A, left), but only upon 
inhibition of the proteasome with MG132 for 
15h (Figure 4A, left). The UbG76V-EGFP SH 
clones were used in experiments such as those 
described above. The western blotting showed 
that none of the conditions tested caused the 
accumulation of a 38 kDa band corresponding 
to the ubiquitin-EGFP fusion protein (Figure 
4B, left), except when the culture media was 
supplemented with MG132 (Figure 4B, left). A 
stable SH clone expressing the Ub-M-EGFP 
fusion protein, which is not degraded in the 
proteasome owing to rapid excision of the 
ubiquitin moiety by ubiquitin hydrolases 
(16;22), was used to control that the expression 
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of the reporter was not affected by the 
incubation conditions. This Ub-M-EGFP clone 
showed no differences in the expression of 
EGFP in any of the conditions tested (Figure 
4B, right). The behaviour of HIF1α in these 
cells was like that of the parental SH clone 
(Figure 4B). Our results indicate that 
proteasome activity is preserved both under OD 
and OGD, and that the stability after 
reoxygenation of HIF1α induced by OGD 
cannot be explained by proteasomal 
inactivation.   
The activity of pVHL is required for 
degradation of HIF1α after reoxygenation. We 
next examined the involvement of pVHL in the 
differential stability of HIF1α protein after 
reoxygenation.  We subjected RCC4 cells 
(which do not naturally express pVHL), and a 
derivative clone over-expressing pVHL from a 
plasmid (RCC4/pVHL), to OD or OGD, 
followed by one hour of reoxygenation. The 
behaviour of HIF1α expression in the 
RCC4/pVHL cells was similar to that seen in 
the SH cells (figure 5, left panel), while in the 
pVHL-deficient RCC4 cells, HIF1α was 
constitutively expressed under normoxia and 
did not experience the glucose-induced 
differences in stability after reoxygenation 
(Figure 5, right panel). This suggests that a) the 
behaviour of HIF1α after reoxygenation of the 
SH cells is not exclusive to this cell line, and b) 
pVHL is involved in the degradation of HIF1α 
after the reoxygenation following a period of 
anoxia. 
The hydroxylation of HIF1α at 
reoxygenation after OGD conditions is 
reduced. The proline hydroxylation catalysed 
by PHD is crucial for the oxygen-dependent 
degradation of HIF1α (4). Thus, we examined 
whether OGD conditions could lead to impaired 
hydroxylation of HIF1α after reoxygenation. 
Analysis of total cellular extracts by Western 
blotting with an antibody specifically 
recognising hydroxy-Pro564 in human HIF1α 
showed large differences in the proportion of 
hydroxylated-HIF1α. One hour of 
reoxygenation after OD in the presence of the 
proteasome inhibitor MG132 (to prevent the 
rapid degradation of HIF1α after 
reoxygenation) produced a higher proportion of 
hydroxylated HIF1α than after OGD (Figure 6). 
When the PHD inhibitor DMOG was added 
instead of MG132, the oxygen-dependent 
hydroxylation of HIF1α after OD was inhibited 
and HIF1α was not degraded (Figure 6).  We 
hypothesised that the oxygen-dependent 
hydroxylation of HIF1α was impaired after a 
long period of OGD. This could be caused 
either by a reduction of PHD enzyme 
activity/abundance or by changes in the 
availability of substrates or inhibitors affecting 
this reaction. We first tested whether the 
abundance of PHD2, the main isoform involved 
on HIF1α hydroxylation (23) was affected by 
OGD and we found it was not the case (Figure 
6). Under our conditions, the physical diffusion 
of atmospheric oxygen into the medium at 
reoxygenation seems to be a rapid process, 
based on the fast disappearance of HIF1α 
during reoxygenation of the glucose-treated 
group (Figure 3 and supplementary figure S3, 
as well as previous data (1)).  Thus, it is 
unlikely that oxygen availability could be 
limiting during reoxygenation after OGD.   
Altered levels of Krebs cycle 
metabolites after OGD might limit HIF1α 
hydroxylation in the presence of oxygen. The 
hydroxylation reaction catalysed by PHD2 also 
depends on α-ketoglutarate as co-substrate, and 
its activity has been shown to be inhibited by 
metabolites of the tricarboxylic cycle such as 
succinate (which is also the product of the 
hydroxylation reaction) and fumarate, the latter 
being the most effective as an inhibitor (24;25). 
Thus, we carried out GC-MS analysis on 
extracts prepared from SH cells to quantitate 
the relative abundance of alpha-ketoglutarate, 
succinate and fumarate at one h of 
reoxygenation after a 15 h treatment under OD 
or OGD. Our data showed that the abundance 
of α-ketoglutarate and succinate was 
significantly reduced in the OGD group relative 
to control (figures 7A and 7B). While OD 
reduced the hydroxylation inhibitor fumarate, 
the abundance of fumarate after OGD tended to 
be even higher than in controls (Figure 7C). 
The abundance of α-ketoglutarate or succinate 
in the OD group was not significantly different 
from the control group. The ratio (mean±SEM) 
α-ketoglutarate/fumarate was 0.0065±0.0015 in 
controls. This value was significantly reduced 
(one way ANOVA, p<0.05) in OGD 
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(0.0015±0.0005), while it was not statistically 
different from control in OD (0.0097±0.0030). 
The lower ratio between α-ketoglutarate 
(reaction substrate) and fumarate (inhibitor) in 
the OGD group prompted us to speculate 
whether these metabolites would play a role in 
the stabilisation of HIF1α by inhibiting HIF1α 
hydroxylation. Thus, we treated SH cells for six 
hours with 20 mM monoethyl fumarate (me-f, 
figure 7D) in the presence of glucose under 
normoxia, in order to increase the intracellular 
availability of fumarate (26). Western blot 
analysis showed that the treatment with me-f 
prevented HIF1α degradation under normoxic 
conditions (Figure 7D). In all, our data indicate 
that alterations in the abundance of metabolites 
could play a regulatory role in the expression of 
HIF1α, and could partly contribute to the 
glucose-dependent differences in HIF1α 
stability at reoxygenation. 
 
DISCUSSION 
 
Our study shows that the induction of HIF1α 
protein during anoxia is strongly affected by the 
prolonged absence of glucose in neuroblastoma 
cells. The effects of the absence of glucose are 
manifested in two ways: a) by diminished 
induction and reduced transcriptional effects of 
HIF1α, and b) by the acquired resistance of 
HIF1α against the oxygen-induced degradation. 
According to these results, severe ischemia is 
expected to induce a lower transcriptional 
activity of HIF1α than mild ischemia or 
hypoxia. Moreover, oxygen availability at 
reperfusion after severe ischemia might not 
induce rapid HIF1α degradation, whereas 
oxygen will readily induce full degradation of 
HIF1α after a period of mild ischemia or 
hypoxia. Our results confirm and extend 
previous observations by Vordermark et al., 
who described a full activation of HIF1α 
expression in tumour cell lines only in the 
presence of glucose during hypoxia, which 
helped to explain the previously observed 
uncoupling between HIF1α expression and 
hypoxic areas in solid tumours (27).  It stands 
to reason there may be a feedback mechanism 
to prevent the HIF-mediated up-regulation of 
glycolytic enzymes when no glucose is 
available, since no immediate benefit would 
derive from it and may otherwise contribute to 
deplete the already strained cellular energy 
stores.   
Several lines of evidence suggest that 
the serine-threonine kinase mammalian target 
of rapamycin (mTOR) may bridge glycolytic 
flux and the expression of HIF1α. This kinase is 
part of a multi-protein complex named 
mTORC1 that receives input from mitogenic as 
well as energy-sensing pathways and, in turn, 
promotes protein synthesis and cell growth 
(28). This complex has also been put forward as 
a positive regulator of HIF1α function (29;30). 
Our results agree with a previous report that 
also described decreased HIF1α expression 
during OGD (31) and suggested this might be 
due to inhibition of mTOR signalling by 
increased AMPK activity. Other evidences 
support a negative role of AMPK for HIF1α 
expression (32). We know that in our 
experimental model, ATP reduction is more 
severe after OGD than after OD (14), so it is 
plausible that AMPK activity could be higher 
under OGD conditions, as described by 
Laderoute et al. (33). Nevertheless, there may 
also be mTORC1 inhibition in the absence of 
glucose that is independent of AMPK (34). 
Thus, whether an AMPK-dependent or 
independent mechanism lies behind the reduced 
levels of expression of HIF1α in our OGD 
model should deserve separate investigation. 
We report how the HIF1α protein that is 
expressed under conditions of OGD displays 
resistance against the reoxygenation-induced 
degradation that otherwise occurs in the 
presence of glucose. This phenomenon was not 
due to inhibition of the general process of 
protein degradation in the proteasome but 
seemed to be due to decreased prolyl-
hydroxylation of HIF1α. This effect occurred 
alongside alterations in the abundance of 
tricarboxylic cycle metabolites (low α-
ketoglutarate/fumarate ratio) that are directly 
involved in the regulation of PHDs (25). 
Despite the effects of such metabolites have 
been studied in heritable alterations of 
tricarboxylic acid cycle enzyme expression and 
in cancer (24;26), we are not aware of other 
studies like ours where metabolic regulation 
induced by environmental changes correlated 
with HIF1α stability through control of prolyl-
 8
hydroxylation. Thus, in our study, OGD 
conditions caused significantly diminished 
abundance of α-ketoglutarate and succinate 
relative to control cells. The α-ketoglutarate 
data coincide with a study by Robert Vanucci’s 
group in the early 90’s that reported decreased 
abundance of α-ketoglutarate after ischemia in 
rat brain (35). On the other hand, we found in 
our model that fumarate abundance was higher 
at reoxygenation after OGD than after OD, and 
that the α-ketoglutarate/fumarate ratio was 
greatly reduced after OGD versus OD or 
control conditions (Figure 7C). In our cells, an 
increase in fumarate intracellular abundance by 
supplementation of the medium with monoethyl 
fumarate caused the up-regulation of HIF1α 
under normoxic conditions (Figure 7D), which, 
according to the literature, would be caused by 
inhibition of hydroxylases targeting HIF1α 
(25;26). The observed changes in metabolite 
abundance induced by OGD, results in an 
substrate/inhibitor ratio that would be less 
favourable for HIF1α hydroxylation. In keeping 
with this, previous data indicate that induction 
of HIF1α expression in normoxia by 
monoethyl-fumarate can be reverted by 
supplementation with a membrane-permeable 
form of α-ketoglutarate (26). 
Regarding the possible role of the 
extended expression of HIF1α beyond 
reoxygenation after OGD, a recent report by 
Filiano and colleagues has shown how 
transglutaminase 2, which is increased after 
subjecting RA-differentiated SH cells to OGD 
and is protective against OGD-induced cell 
death (36), binds HIF1 β and dampens HIF1 
transcriptional effects (36). The evidence 
provided in that report suggests that HIF1 
expression induced by OGD would play a 
detrimental role in SH cell survival. This is 
controversial, since HIF1α inhibition caused 
negative effects on the survival of SH cells to 
an ischemic insult followed by reoxygenation, 
owing to a shift in the cellular redox 
environment towards a more oxidising state 
(37). Building on those reports and in 
concordance with data presented in our 
previous publication (14), it is tempting to 
speculate that the low-key sustained expression 
of HIF1α after OGD and reoxygenation may 
partly account for the activation of the genetic 
programme that leads to OGD-induced delayed 
cell death in our model. Nevertheless, proper 
demonstration of this hypothesis lies beyond 
the scope of this manuscript, and shall await 
further research.  
In conclusion, we present data 
suggesting that HIF1α protein expression could 
be regulated by changes in cellular metabolism 
that reflect environmental cues. In one hand, 
HIF1α would be regulated by a mechanism 
purely dependent on the presence of oxygen, 
which in the presence of glucose, would result 
in a high level of activation of HIF1α and 
enhancement of ATP production by glycolysis 
with rapid clearance of HIF1α after 
reoxygenation when aerobic metabolism is 
resumed. On the other hand, our results support 
the involvement of another mechanism driven 
by alterations in the abundance of tricarboxylic 
acid cycle metabolites that would restrain the 
expression of HIF1α in the absence of both 
oxygen and glucose, thus preventing 
unnecessary activation of glycolysis. This 
mechanism would maintain HIF1 activity at 
reoxygenation while the metabolic profile 
remains altered.  Our findings lend further 
support to the idea that it might be possible to 
regulate HIF1α expression up to a certain extent 
independently of oxygen levels by coupling 
metabolism and prolyl-4-hydroxylase activity 
(38;39), in metabolic contexts that may extend 
beyond the range of situations where the effects 
of metabolites on HIF1α expression have been 
successfully explored so far (24;26;40).  
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FIGURE LEGENDS 
 
Figure 1. The absence of glucose during anoxia blunts the increase in HIF1 expression and 
binding to DNA. A. Western blot showing the relative expression of HIF1 subunits α and β in total 
extracts prepared from cells treated under anoxia for 15h in either the presence (OD: glucose +, 
anoxia +) or absence of glucose (OGD: glucose -, anoxia +), or under control conditions (glucose +, 
anoxia -). The membrane was re-blotted with an antibody against α-actin to control equal loading. 
B. Quantification of HIF1α by densitometry of western blots. Data were expressed as fold change 
relative to the OGD group and are represented as the average ±SEM of 10 to 17 independent 
experiments. Statistical analysis was by one-way ANOVA followed by Mann-Whitney post-test. 
OD vs. OGD, * p< 0.05. C. ELISA quantification of HIF1α in total cell extracts prepared from SH 
cells treated as above for the same period of time, as indicated. Data were expressed as pg of HIF1 
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per µg of total cellular protein and are represented as the average ±SEM of seven independent 
experiments.  Statistical analysis was by one-way ANOVA followed by Bonferroni post-test. N.D.: 
not detectable; OD vs. OGD,  ** p<0.01. D. Relative binding of HIF1 in nuclear extracts prepared 
from cells treated as above to an oligonucleotide containing an HRE. Data were normalised by the 
total protein content, expressed relative to the value of the control group and are represented as the 
average of four independent experiments ±SEM. Statistical analysis was by one-way ANOVA 
followed by Bonferroni post-test. OD vs. OGD, ** p< 0.01. 
 
Figure 2.  OGD reduces HIF-mediated transcription and dampens the induction of HIF1 
target genes. A. Quantification of the relative HIF transcriptional activity in transient transfection 
experiments with an HRE-dependent luciferase reporter (wtHRE) in SH cells. A vector containing a 
mutant HRE (mutHRE) was used as a negative control. Results were normalised by Renilla 
luciferase activity and expressed as fold activation relative to the control group. Data are 
represented as the average ±SEM of five independent experiments, and were analysed by one-way 
ANOVA followed by Bonferroni test. OD (O2-, G+) vs. control (O2+, G+), or OD vs. OGD (O2-, G-
) *** p<0.001. B and C. Induction of HIF targets (VEGF, hexokinase II, GLUT1) as a consequence 
of the treatments described above. Secreted VEGF was detected by ELISA, whereas hexokinase II 
and GLUT1 in total cellular extracts were detected by immunoblotting. VEGF data were normalised 
by the value of the control condition and were expressed as relative abundance. Data are 
represented as the average ±SEM of four independent experiments, and were analysed by one-way 
ANOVA followed by Bonferroni post-test (** p<0.01).  
 
Figure 3. HIF1α produced during OGD becomes resistant to degradation even after 
reoxygenation. A. The expression of HIF1α protein was assessed by immunoblotting in total cell 
extracts prepared from cells incubated either in control conditions (anoxia -, glucose +), or for 15h 
in OD (15h anoxia, glucose +) or OGD (15h anoxia, glucose -) conditions, followed by one, three or 
six h after reoxygenation, as indicated.  B. Expression of HIF1α in cells incubated under anoxia for 
6h in the presence or absence of glucose and 30 min after reoxygenation. Blots in both panels were 
also probed with the α-actin antibody to provide a control of the protein loading.  
 
Figure 4. The resistance of HIF1α to oxygen is not due to impaired proteasome activity. A. 
Cells expressing either the proteasome activity reporter Ub-G76V-EGFP (left panels) or the control 
reporter Ub-M-EGFP (right panels) were incubated for 15 h in the presence or absence of 
proteasome inhibitor MG132 (10 µM), as indicated. Micrographs show fluorescence of EGFP 
(EGFP) or a phase-contrast image of the same field (PC). B. Detection of the Ub-G76V-EGFP (left 
panels) or Ub-M-EGFP (right panels) reporters with an antibody against GFP by immunoblotting of 
total cellular extracts prepared in the conditions indicated. Media were supplemented with 10 μM 
MG132 as indicated. The white arrowhead (left panels) indicates the position of the Ub-G76V-
EGFP fusion protein. Increased expression of the fusion protein owing to inhibition of the 
proteasome allows low-efficiency cleavage of the ubiquitin moiety and detection of free EGFP 
(black arrowhead, (16)). An unidentified band of lower molecular weight was also detected 
(asterisk). The right panel shows constitutive expression of free EGFP in the clone expressing the 
Ub-M-EGFP fusion protein. As a control, HIF1α was detected on the same blots. They were also 
probed with an antibody against tubulin-β to provide a loading control. 
 
Figure 5. The activity of pVHL is required for degradation of HIF1α after reoxygenation. The 
expression of HIF1α protein was analysed in wild type RCC4 cells (which lack pVHL, right panel) 
and a clone transfected with a plasmid expressing pVHL to rescue the mutation (RCC4/pVHL, left 
panel). The two clones were subjected to control, OD, or OGD conditions for 15h. The blots were 
probed with the α-actin antibody to provide a loading control. 
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Figure 6. The hydroxylation of HIF1α is reduced after OGD followed by one hour of 
reoxygenation. Detection of hydroxy-Pro564-HIF1α by immunoblotting of total cellular extracts 
prepared from SH cells one hour after reoxygenation following OD (glucose +) or OGD (glucose -) 
for 15h, as indicated.  Supplementation of the medium with 10 µM MG132 prior to anoxia 
prevented HIF1α degradation following reoxygenation after OD treatment and allowed detection of 
hydroxylation under this condition.  PHD inhibitor DMOG (1 mM) was added prior to anoxia  to a 
separate dish to control for the specificity of the signal. Total HIF1α and PHD2 protein levels were 
subsequently measured on the same blot. ATP synthase-β (ATPS-β) was used to control for equal 
loading.  
 
Figure 7. OGD induces alterations in tricarboxylic acid (TCA) cycle metabolites that may 
affect HIF1α hydroxylation and expression. Intracellular levels of some TCA cycle metabolites 
that may affect HIF1α expression:  α-ketoglutarate (A), succinate (B) and fumarate (C), were 
detected by GC-MS (see methods) in the conditions indicated. Normalised data were expressed 
relative to the abundance of the control group, and are shown as the average ±SEM of 7 
independent experiments. Data on α-ketoglutarate (A, OGD vs. control, * p<0.05) were analysed by 
Krustall Wallis test for non-parametric data followed by a Dunn’s multiple comparison test, while 
succinate (B, OGD vs. control, *** p<0.005) and fumarate levels (C, OD vs. control, ** p<0.01) 
were analysed by one-way ANOVA followed by Bonferroni post-test. D. Supplementation of the 
medium with 20 mM monoethyl fumaric acid was enough to increase HIF1α expression in cells 
under control conditions. An OGD sample was included as a positive control. ATP synthase-β was 
used as a loading control.  







